Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 7, 2008 - Issue 6
Submit an article Journal homepage
141
Views
21
CrossRef citations to date
0
Altmetric
Drug Safety Evaluation

The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice

Umesh U Tamhane University of Michigan Cardiovascular Center, VA Ann Arbor Healthcare System, Division of Cardiovascular Medicine, Department of Medicine, 2A394, 1500 E. Medical Center Drive, MI 48109-5853, Ann Arbor, USA +1 734 232 4276; +1 734 764 4142; [email protected]
, MD &
Hitinder S Gurm University of Michigan Cardiovascular Center, VA Ann Arbor Healthcare System, Division of Cardiovascular Medicine, Department of Medicine, 2A394, 1500 E. Medical Center Drive, MI 48109-5853, Ann Arbor, USA +1 734 232 4276; +1 734 764 4142; [email protected]
, MD FACC
Pages 809-819 | Published online: 04 Nov 2008

Bibliography

  • Schrör K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 2003;15(2):71-80
  • Kereiakes DJ, Runyon JP, Broderick TM, Shimshak TM. IIb's are not IIb's. Am J Cardiol 2000;85(8A):C23-31
  • Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2001;37(8):2059-65
  • Blankenship JC. Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors. Am Heart J 1999;138(4 Suppl1):s287-96
  • Coller BS. Monitoring platelet GP IIb/IIIa [corrected] antagonist therapy. Circulation 1997;96(11):3828-32
  • Package insert for abciximab (ReoPro). Indianapolis, IN: Eli Lilly & Co.; 1998
  • Simon DI, Xu H, Ortlepp S, et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997;17(3):528-35
  • Van Den Brand M, Laarman GJ, Steg PG, et al. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial. Eur Heart J 1999;20(21):1572-8
  • Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000;284(12):1549-58
  • Muhlestein JB, Karagounis LA, Treehan S, Anderson JL. “Rescue” utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol 1997;30(7):1729-34
  • Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol 2003;42(11):1886-9
  • Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 2007;28(4):443-9
  • Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98(8):734-41
  • Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000;35(4):915-21
  • Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344(25):1895-903
  • Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346(13):957-66
  • Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003;42(11):1879-85
  • Ellis SG, Tendera M, De Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008;358(21):2205-17
  • Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358(21):2218-30
  • Thiele H, Schindler K, Friedenberger J, et al. Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarction Trial. Circulation 2008;118(1):49-57
  • Bellandi F, Maioli M, Gallopin M, et al. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Cathet Cardiovasc Interv 2004;62(2):186-92
  • Wohrle J, Grebe OC, Nusser T, et al. reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of Abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 2003;107(14):1840-3
  • Kakkar AK, Moustapha A, Hanley HG, et al. Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Cathet Cardiovasc Interv 2004;61(1):31-4
  • Galache Osuna JG, Sanchez-Rubio J, Calvo I, et al. [Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial]. Rev Esp Cardiol 2006;59(6):567-74
  • Marmur JD, Poludasu S, Agarwal A, et al. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention. J Invasive Cardiol 2006;18(11):521-6
  • Fischell TA. “Bolus-only” glycoprotein IIb/IIIa inhibitor use for elective percutaneous coronary intervention: maybe less is more? Am Heart J 2006;152(5):812-4
  • Bertrand OF, De Larochelliere R, Rodes-Cabau J, et al. A randomized study comparing same-day home discharge and Abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Circulation 2006;114(24):2636-43
  • Bertrand OF, Rodes-Cabau J, Larose E, et al. One-year clinical outcome after abciximab bolus-only compared with abciximab bolus and 12-hour infusion in the randomized early discharge after transradial stenting of coronary arteries (EASY) study. Am Heart J 2008;156(1):135-40
  • Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001;357(9272):1915-24
  • Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation 2002;106(3):379-85
  • Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in preventing ischemic complications. J Am Coll Cardiol 1997;30(1):149-56
  • The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349(9063):1429-35
  • The EPIC Investigators. Use of a Monoclonal antibody directed against the platelet Glyc7oprotein IIb/IIIa receptor in High-risk coronary angioplasty. N Engl J Med 1994;330(14):956-61
  • The Epilog Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336(24):1689-97
  • EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352(9122):87-92
  • Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002;113(1):1-6
  • Ndrepepa G, Kastrati A, Mehilli J, et al. Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions. Circulation 2006;114(19):2040-6
  • Alexander KP, Newby LK, Cannon CP, et al. Acute coronary care in the elderly, Part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007;115(19):2549-69
  • Alexander KP, Newby LK, Armstrong PW, et al. Acute coronary care in the elderly, Part II: ST-segment-elevation myocardial Infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration With the Society of Geriatric Cardiology. Circulation 2007;115(19):2570-89
  • Mehilli J, Ndrepepa G, Kastrati A, et al. Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from intracoronary stenting and antithrombotic regimen: rapid early action for coronary treatment 2 trial. Am Heart J 2007;154(1):e1-7 158
  • Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. J Am Coll Cardiol 2000;36(2):381-6
  • Bhatt DL, Marso SP, Lincoff AM, et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35(4):922-8
  • Mehilli J, Kastrati A, Schuhlen H, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004;110(24):3627-35
  • Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344(25):1888-94
  • Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008;299(15):1788-99
  • Aster RH, Curtis BR, Bougie DW, et al. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost 2006;4(3):678-9
  • Zeymer U. Eptifibatide versus abciximab in primary PCI for acute ST elevation myocardial infarction. Late-breaking clinical trial presented at the American Heart Association's scientific sessions. Orlando, FL, 2007; November 4-7
  • Gurm HS, Smith DE, Collins JS, et al. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol 2008;51(5):529-35
  • Raveendran G, Ting HH, Best PJ, et al. Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction. Mayo Clin proc 2007;82(2):196-202
  • Midei MG, Coombs VJ, Lowry DR, et al. Clinical outcomes comparing eptifibatide and abciximab in ST elevation acute myocardial infarction patients undergoing percutaneous coronary interventions. Cardiology 2007;107(3):172-7
  • Ellis SG, Tendera M, De Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008;358(21):2205-17
  • Sabatine MS, Hamdalla HN, Mehta SR, et al. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. Am Heart J 2008;155(5):910-7
  • Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY Study. JAMA 2005;294(10):1224-32
  • Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358(9281):527-33
  • Steinhubl SR, Berger PB, Mann Iii JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288(19):2411-20
  • Casterella PJ, Revenaugh JR, Burke JL, et al. Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. J Invasive Cardiol 2008;20(3):94-8
  • Kastrati A, Mehilli J, Schuhlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with Clopidogrel. N Engl J Med 2004;350(3):232-8
  • The TIMI Study Group. Definitions used in TIMI trials. Available from: http://www.timi.org (Last accessed June 27) 2008
  • Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006;295(13):1531-8
  • Pretreatment with a high loading dose of clopidogrel and value of abciximab during primary coronary intervention in patients with acute myocardial infarction: results of the randomized BRAVE-3 trial presented by Dr Julinda Mehilli at the SCAI-ACC i2 Summit/American College of Cardiology Annual Scientific Session, Chicago, IL, March/April 2008. Available from: http://www.cardiosourcecom/clinicaltrials/trialasp?trialID=1660 (Accessed June 28, 2008)
  • Schwarz M, Meade G, Stoll P, et al. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res 2006;99(1):25-33
  • Stoll P, Bassler N, Hagemeyer CE, et al. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler Thromb Vasc Biol 2007;27(5):1206-12
  • Gurm HS, Smith DE, Chetcuti SJ, et al. Temporal trends, safety, and efficacy of bivalirudin in elective percutaneous coronary intervention: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. J Interv Cardiol 2007;20(3):197-203

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.